Bausch Health Companies BHC Price Appreciation Credit — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch Health Companies in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bausch Health Companies's price appreciation credit — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bausch Health Companies's price appreciation credit — revenue?
- Bausch Health Companies (BHC) reported price appreciation credit — revenue of $2M in Q1 2026.
- How has Bausch Health Companies's price appreciation credit — revenue changed year-over-year?
- Bausch Health Companies's price appreciation credit — revenue decreased by 0.0% year-over-year, from $2M to $2M.
- What is the long-term trend for Bausch Health Companies's price appreciation credit — revenue?
- Over 3 years (2022 to 2025), Bausch Health Companies's price appreciation credit — revenue has grown at a 21.6% compound annual growth rate (CAGR), from $10M to $18M.
- What does price appreciation credit — revenue mean?
- This metric represents the revenue generated from price appreciation credits associated with specific pharmaceutical or medical product contracts. It reflects the financial impact of contractual adjustments or performance-based credits tied to the market valuation or pricing changes of the underlying products. This segment provides insight into the company's ability to capture value through contractual pricing mechanisms within its diversified product portfolio.